PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS

INTRODUCTION: Diffuse low-grade gliomas (DLGG) treated with temozolomide (TMZ) can develop somatic hypermutation. We present data on the incidence and prognostic importance of somatic hypermutation in IDH-mutant DLGGs. METHODS: We analyzed 120 patients treated on a phase II clinical trial of TMZ for...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Yu, Yao, Hilz, Stephanie, Grimmer, Matthew, Solomon, David, Choi, Serah, Wahl, Michael, Mazor, Tali, Hong, Chibo, Shai, Anny, J Phillips, Joanna, Villanueva-Meyer, Javier, McDermott, Michael, Haas-Kogan, Daphne, Taylor, Jennie, Butowski, Nicholas, Clarke, Jennifer, Berger, Mitchel, Molinaro, Annette, Chang, Susan, Costello, Joseph, Oberheim Bush, Nancy Ann
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216686/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.685
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars